Who is sponsoring NCT03473314?

NCT03473314 is sponsored by University of British Columbia.

What drugs are being tested in NCT03473314?

Interventions in NCT03473314: Nitric Oxide gas at 160ppm.

What condition does NCT03473314 study?

NCT03473314 studies Non-Tuberculous Mycobacterial Pneumonia.

Is NCT03473314 still recruiting?

NCT03473314 is currently completed. Last updated 29 July 2020.

Last reviewed 2020-07-29 · How we verify

NCT03473314

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for Adult With Non-Tuberculous Mycobacteria Infection

Completed Phase 2 Last updated 29 July 2020

What this trial tests

Phase 2 trial testing Nitric Oxide gas at 160ppm in Non-Tuberculous Mycobacterial Pneumonia in 1 participant. Completed in 21 July 2020.

Timeline

9 March 2018

Primary endpoint
11 July 2020

21 July 2020

Quick facts

Lead sponsor	University of British Columbia
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	9 March 2018
Primary completion	11 July 2020
Estimated completion	21 July 2020
Sites	1 location across Canada

Drugs / interventions tested

Nitric Oxide gas at 160ppm — full drug profile →

Conditions studied

Non-Tuberculous Mycobacterial Pneumonia — all drugs for Non-Tuberculous Mycobacterial Pneumonia →

Sponsor

University of British Columbia

Who can join

19 and older, any sex, with Non-Tuberculous Mycobacterial Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An open labeled Study (NCT03331445) is demonstrating encouraging safety and efficacy results for most subjects receiving 160ppm nitric oxide gas (gNO) for treatment of non-tuberculous mycobacteria (NTM) over a 15 day treatment regimen. In one subject, who had a reduction in sputum culture concentration of Bacterium bolletii from plus 3 to plus 1 corresponding to a 2-3 log10 cfu/gm reduction during the treatment, the one-week post treatment follow-up sputum culture had increased to plus 2. It is hypothesized that a longer treatment period may be necessary to fully eradicate NTM from the sputum culture in chronic lung disease. This study will extend the period of gNO exposure for a prolonged period of time (3 months) to attempt to fully eradicate the NTM in this single subject. This study will transition from the medical clinic to supervised delivery in the patient's home environment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Toward better cures for <i>Mycobacterium abscessus</i> lung disease.
Dartois V, Dick T. · · 2024 · cited 10× · PMID 39360834 · DOI 10.1128/cmr.00080-23
Beyond antibiotics: recent developments in the diagnosis and management of nontuberculous mycobacterial infection.
Gleeson LE, Waterer G. · · 2022 · cited 9× · PMID 36337137 · DOI 10.1183/20734735.0171-2021

Verify or expand the search:

Other recruiting trials for Non-Tuberculous Mycobacterial Pneumonia

Currently open trials in the same condition.

NCT06602869 — Cellular Markers in Treated or Untreated Non-tuberculous Mycobacterial Respiratory Infection in Patients With Cystic Fib · recruiting
NCT06522347 — Mycobacteria Registry Study: Prospective Observational Study in Austria · recruiting
NCT06413459 — Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic F · recruiting

Other University of British Columbia trials

Trials by the same sponsor.

NCT07340970 — Sensory Stimuli During Cesarean Delivery · not yet recruiting
NCT07481201 — Phenylalanine Requirements in the Menstrual Phases · NA · not yet recruiting
NCT07492095 — Leucine Requirements in School-Age Children · NA · not yet recruiting
NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03473314 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
Last refreshed: 29 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03473314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing